Tian pharma shares of nail-sprinkling nylon tablets through consistency evaluation

Metaper nylon tablets are a hormone-based drug, widely used in clinical applications, mainly used to treat rheumatic diseases, collagen diseases, skin diseases, allergic state, eye diseases, respiratory diseases and so onDeveloped by Famacia Puqiang and is now owned by Pfizer in the United States, the drug was launched in the United States in 1954 under the name MedrolThe drug's domestic listed companies are Tianpharma Shares and Pfizer of the United Statescompany, Apus nylon tablets, was approved by the U.SFood and Drug Administration's ANDA (AAccording to the Opinions of the General Office of the State Council on Carrying out Consistent Evaluation of The Quality and Efficacy of Generic Drugs issued by the General Office of the State Council (State Office issued No8 of 2016), the company's amethyst nylon tablets belong to the domestic and foreign common line and can apply for domestic consistency evaluation according to foreign approval dataTherefore, the company submitted to the State Drug Administration domestic and foreign common line production consistency evaluation application, was accepted on December 21, 2018, and recently obtained the "drug supplementary application approval", is the first domestic through the match-perm nylon film consistency evaluation of the enterpriseUp to now, the company has invested about 4.66 million yuan in research and development research and development projects in the domestic consistency evaluation of the a-plate nylon pieceAccording to the nationally enlarged version of the hospital data (including urban public hospitals, county-level public hospitals, urban community hospitals, township hospitals), sales of 2016-2018 were 260 million yuan, 370 million yuan and 440 million yuan, respectivelyIn 2018, the company's domestic market share of the adpan nylon pieces accounted for about 25%.